Recent blog posts
NCT07510217 Dexmedetomidine Hydrochloride Post-Traumatic Headache Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07510217 Dexmedetomidine Hydrochloride Post-Traumatic Headache Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07510217 clinical trial report covering Dexmedetomidine Hydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white spac
Read →
NCT07509086 IL-15-Armored CAR-T(The First Hospital of Jilin University) Multiple Myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07509086 IL-15-Armored CAR-T(The First Hospital of Jilin University) Multiple Myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07509086 clinical trial report covering IL-15-Armored CAR-T(The First Hospital of Jilin University), Phase 2, endpoints, sponsor, geography, readout tim
Read →
NCT07509047 Aluminium Chloride Cholera Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07509047 Aluminium Chloride Cholera Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07509047 clinical trial report covering Aluminium Chloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07509424 Sintilimab Locally Advanced Rectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07509424 Sintilimab Locally Advanced Rectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07509424 clinical trial report covering Sintilimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07510334 Ipilimumab Metastatic Clear Cell Renal Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07510334 Ipilimumab Metastatic Clear Cell Renal Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07510334 clinical trial report covering Ipilimumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07509515 QLC5513 Triple Negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07509515 QLC5513 Triple Negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07509515 clinical trial report covering QLC5513, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07510594 Anlotinib Dihydrochloride Large cell neuroendocrine carcinoma of lung Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07510594 Anlotinib Dihydrochloride Large cell neuroendocrine carcinoma of lung Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07510594 clinical trial report covering Anlotinib Dihydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07509892 TQH-3906 Systemic Lupus Erythematosus Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07509892 TQH-3906 Systemic Lupus Erythematosus Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07509892 clinical trial report covering TQH-3906, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07509112 Semaglutide (Novo Nordisk) Methamphetamine abuse Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07509112 Semaglutide (Novo Nordisk) Methamphetamine abuse Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07509112 clinical trial report covering Semaglutide (Novo Nordisk), Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07512700 Venetoclax Acute Monocytic Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07512700 Venetoclax Acute Monocytic Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07512700 clinical trial report covering Venetoclax, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07508995 Sonrotoclax Chronic Lymphocytic Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07508995 Sonrotoclax Chronic Lymphocytic Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07508995 clinical trial report covering Sonrotoclax, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07511972 Pembrolizumab Colorectal Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07511972 Pembrolizumab Colorectal Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07511972 clinical trial report covering Pembrolizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →